Epstein–Barr virus
Virus of the herpes family
Follow Epstein–Barr virus on Notably News to receive short updates to your email — rarely!
We include updates on Multiple sclerosis, Lupus, Multiple myeloma, Infectious mononucleosis, Alice in Wonderland syndrome, Stomach cancer, Burkitt lymphoma, Diffuse large B-cell lymphoma, Leiomyosarcoma, Hairy leukoplakia, Nasopharyngeal carcinoma, T-cell lymphoma, MOG antibody disease, Mosquito bite allergy, Plasmacytoma, Primary central nervous system lymphoma ... and more.
| 2024 |
Multiple myeloma
FDA expanded CAR T-Cell therapy approval to include multiple myeloma patients who have relapsed after only a single line of treatment, broadening treatment options for patients earlier in their disease progression.
|
| September 2023 |
Multiple myeloma
Motixafortide (Aphexda) was approved for medical use in the United States, expanding treatment options for multiple myeloma.
|
| August 2023 |
Multiple myeloma
Talquetamab (Talvey) and elranatamab (Elrexfio) were approved for medical use in the United States, providing new treatment options for multiple myeloma patients.
|
| 2022 | A groundbreaking study of 10 million soldiers' historical blood samples revealed a critical link between Epstein-Barr virus infection and multiple sclerosis, showing that the risk of multiple sclerosis increases over 30-fold after EBV infection. |
| 2022 | A large-scale study of 10 million people over 20 years suggested EBV as the leading cause of multiple sclerosis, revealing that a recent EBV infection increases the risk of developing multiple sclerosis by 32-fold. |
| September 2022 |
Lupus
Researchers at the University of Erlangen-Nuremberg published groundbreaking results of a lupus treatment using genetically altered CAR T cells. Five patients (four women and one man) received transfusions that eliminated aberrant B cells, successfully driving the disease into remission and allowing patients to discontinue lupus medication.
|
| February 2022 |
Multiple myeloma
Ciltacabtagene autoleucel (Carvykti) was approved for medical use in the United States, indicated for treating adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
|
| 2021 |
Multiple myeloma
FDA approved idecabtagene vicleucel, the first cell-based gene therapy for treating adults with relapsed or refractory multiple myeloma who have received at least four prior therapies.
|
| July 2020 | Researchers reported the first complete atomic model of the Epstein-Barr virus nucleocapsid, which included the icosahedral capsid, capsid-associated tegument complex (CATC), and dodecameric portal – providing a comprehensive structural understanding of the virus's genome translocation apparatus. |
| February 2019 |
Extranodal NK/T-cell lymphoma, nasal type
A phase 2 clinical study sponsored by ViGenCell Inc. begins recruitment for testing cytotoxic T-lymphocyte (CTL) treatment on patients in complete remission from Extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT) to determine if the treatment can prolong remissions.
|
| September 2018 |
Extranodal NK/T-cell lymphoma, nasal type
A study examining the effects of brentuximab vedotin on EBV-positive, CD30-positive lymphomas is estimated to be completed.
|
| 2011 |
Alice in Wonderland syndrome
By month 8 after the initial treatment, the patient's symptoms returned, prompting a second rTMS treatment which again resulted in complete remission.
|
| 2011 |
Alice in Wonderland syndrome
A patient with verbal auditory hallucinations was treated using repetitive transcranial magnetic stimulation (rTMS) on Brodmann's area 40. After two weeks of treatment, the patient experienced full remission of hallucinations and sensory distortions.
|
| August 2011 |
Alice in Wonderland syndrome
By the eighth month after initial treatment, the patient's symptoms of Alice in Wonderland Syndrome returned, prompting a second treatment which again resulted in complete remission.
|
| March 2011 |
Lupus
FDA approved belimumab, a fully human monoclonal anti-BAFF antibody, as a treatment for lupus after the BLISS-76 study tested its effectiveness in targeting B lymphocytes.
|
This contents of the box above is based on material from the Wikipedia articles Multiple myeloma, Alice in Wonderland syndrome, Epstein–Barr virus, Extranodal NK/T-cell lymphoma, nasal type & Lupus, which are released under the Creative Commons Attribution-ShareAlike 4.0 International License.